Evan David Seigerman
Stock Analyst at BMO Capital
(3.46)
# 768
Out of 4,667 analysts
28
Total ratings
41.67%
Success rate
44.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $228 → $208 | $171.73 | +21.12% | 5 | Nov 12, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,300 → $1,190 | $744.50 | +59.84% | 5 | Nov 1, 2024 | |
| MRK Merck & Co. | Maintains: Outperform | $150 → $136 | $99.86 | +36.19% | 2 | Nov 1, 2024 | |
| NVO Novo Nordisk | Maintains: Outperform | $160 → $156 | $102.63 | +52.00% | 4 | Oct 17, 2024 | |
| GPCR Structure Therapeutics | Maintains: Outperform | $83 → $100 | $30.10 | +232.23% | 2 | Jun 7, 2024 | |
| AMGN Amgen | Maintains: Outperform | $336 → $355 | $289.90 | +22.46% | 3 | May 3, 2024 | |
| PFE Pfizer | Reiterates: Outperform | $33 → $36 | $25.13 | +43.26% | 4 | May 2, 2024 | |
| CADL Candel Therapeutics | Maintains: Outperform | $9 → $3 | $4.14 | -27.45% | 1 | May 15, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $40 → $70 | $11.05 | +533.48% | 1 | Dec 12, 2022 | |
| LLY Eli Lilly | Maintains: Outperform | $369 → $396 | $749.92 | -47.19% | 1 | Sep 6, 2022 |
AbbVie
Nov 12, 2024
Maintains: Outperform
Price Target: $228 → $208
Current: $171.73
Upside: +21.12%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $1,300 → $1,190
Current: $744.50
Upside: +59.84%
Merck & Co.
Nov 1, 2024
Maintains: Outperform
Price Target: $150 → $136
Current: $99.86
Upside: +36.19%
Novo Nordisk
Oct 17, 2024
Maintains: Outperform
Price Target: $160 → $156
Current: $102.63
Upside: +52.00%
Structure Therapeutics
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $30.10
Upside: +232.23%
Amgen
May 3, 2024
Maintains: Outperform
Price Target: $336 → $355
Current: $289.90
Upside: +22.46%
Pfizer
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $25.13
Upside: +43.26%
Candel Therapeutics
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $4.14
Upside: -27.45%
Replimune Group
Dec 12, 2022
Maintains: Outperform
Price Target: $40 → $70
Current: $11.05
Upside: +533.48%
Eli Lilly
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $749.92
Upside: -47.19%